Our Team
With a wealth of experience including clinical, scientific, and industry expertise across the radiopharmaceutical, molecular imaging, diagnostics, and medical technology sectors.
Serac Healthcare is developing 99mTc-maraciclatide to address major unmet medical and societal needs
Our highly experienced in-house team has led the development, launch, and successful commercialisation of medical imaging technologies for some of the industry’s leading global players.
We also work very closely with our academic partners from world leading research centres at King’s College London, the University of Leeds and the University of Oxford, as well as our established network of scientific advisors.
Our Board
Mark Rosser, PhD
COO
With more than 25 years working on the development of products for nuclear medicine and molecular imaging, Mark has extensive experience in leading global functional and cross-functional project/programme teams to deliver new products and life cycle opportunities.
James McCutcheon, FCCA
CFO
James is an experienced commercial and finance director with over 30 years of experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast-growing SMEs.
Pat Butler
Board Observer and Advisor
Pat is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank, was formerly a Senior Director at McKinsey & Co., and is a qualified chartered accountant. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.
Management Team
Jon Barnett, PhD
Programme Director
Over 20 years experience in radiopharmaceutical and biopharmaceutical product development and commercial supply. Jon has extensive experience in leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.
Sarah Prideaux-Turner
Financial Controller
Sarah has over 25 years of experience at both the Director and Controller levels in building and running successful finance departments primarily in high-tech, high-growth SME companies. Over the past decade, she has worked in predominantly bio-tech and medical device R&D companies.
